#ACC22 LBTs/ Featured Research one liners:
1. VALOR HCM: MAVACAMTEN at 16 weeks in symptomatic HCM decreased the need of SRT
2. Sodium HF: in HF outpatients low-Na diet of 1500 mg/day was not associated with a reduction in CV events but moderate benefit on QoL by KCCQ
1. VALOR HCM: MAVACAMTEN at 16 weeks in symptomatic HCM decreased the need of SRT
2. Sodium HF: in HF outpatients low-Na diet of 1500 mg/day was not associated with a reduction in CV events but moderate benefit on QoL by KCCQ
3. CHAP: In pregnant women with mild chronic HTN, antihypertensives targeted to a BP <140/90 reduced the incidence of adverse pregnancy outcomes
4. POISE 3: In patients undergoing non cardiac surgery, TRANEXAMIC ACID reduced the risk of bleeding ( non inferiority not met)
4. POISE 3: In patients undergoing non cardiac surgery, TRANEXAMIC ACID reduced the risk of bleeding ( non inferiority not met)
5. PACMAN AMI: ALIROCUMAB in acute AMI along with HI statin resulted in reduction in lipid burden/ coronary plaque regression in non-infarct arteries > 52 weeks
6. SUPER WIN: Personalized serial nutrition education at grocery store increased individual compliance to DASH diet
6. SUPER WIN: Personalized serial nutrition education at grocery store increased individual compliance to DASH diet
7. APOLLO: single ascending dose of SLN360, shows promise in lowering plasma lipoprotein(a) concentrations in patients with elevated levels and no known CVD
8. TRANSLATE TIMI 70: VUPANORSEN reduced non HDLcholesterol by up to 28% in patients on statins
8. TRANSLATE TIMI 70: VUPANORSEN reduced non HDLcholesterol by up to 28% in patients on statins
9. PROMPT HF: EHR based alerts VS usual follow up for outpatients with HFrEF demonstrated increased rates on GDMT at 30 days
10. METEROTIC HF: OMECAMTIV MECARBIL did not improve measures of exercise capacity over a 20-week period in well-treated patients with chronic HFrEF
10. METEROTIC HF: OMECAMTIV MECARBIL did not improve measures of exercise capacity over a 20-week period in well-treated patients with chronic HFrEF
11. DIAMOND: PATIROMER in HFrEF with RAASi hyperkalemia resulted in significantly lower K levels
12. IVVE: INFLUENZA VACCINATION among patients with symptomatic HF in LMICs did not result in a reduction in cardiovascular outcomes compared with placebo.
12. IVVE: INFLUENZA VACCINATION among patients with symptomatic HF in LMICs did not result in a reduction in cardiovascular outcomes compared with placebo.
13. COMPLETE: Among patients with STEMI and multivessel disease undergoing primary PCI, COMPLETE REVASCULARIZATION performed either during or after the index hospitalization was superior to culprit-only revascularization
14. FAME 3: FFR-guided PCI using current-generation DES did not meet criteria for noninferiority vs CABG among patients with angiographic three-vessel disease.
15. FLAVOR: Among patients with an intermediate coronary stenosis, FFR-guided PCI was noninferior to IVUS-guided PCI
15. FLAVOR: Among patients with an intermediate coronary stenosis, FFR-guided PCI was noninferior to IVUS-guided PCI
16. SCORED: SOTAGLIFLOZIN has salutary effects on CV outcomes among patients with T2DM and CKD.
17. PATENS: In patients undergoing cardiac catheterization via transradial access, intra-arterial nitroglycerin was not beneficial in preventing radial artery occlusion
17. PATENS: In patients undergoing cardiac catheterization via transradial access, intra-arterial nitroglycerin was not beneficial in preventing radial artery occlusion
18. PARTITA: VT ablation after 1st appropriate shock was associated with a reduced risk of the combined death, worsening HF hospitalization and less ICD shocks.
19. Phase 2b/ REVERSE IT: BENTRACIMAB is safe in reversing the antiplatelet effect of ticagrelor in healthy adults
19. Phase 2b/ REVERSE IT: BENTRACIMAB is safe in reversing the antiplatelet effect of ticagrelor in healthy adults
20. Phase 2 /PACIFIC AF: In patients with AF, ASUNDEXIAN (Factor XI inhibitor) caused lesser bleeding than Apixaban
21. EDIT – CMD: In patients with angina and non obstructive CAD, DILTIAZEM did not improve vasomotor dysfunction or QOL after 6 wks
21. EDIT – CMD: In patients with angina and non obstructive CAD, DILTIAZEM did not improve vasomotor dysfunction or QOL after 6 wks
22. mAFA II – Consumer led mass screening for AF with confirmation> 93% of detected AF, with OSA being the mc risk factor by smart device
23. LAAO Registry: Peri device leak at 45 day follow up noted in 25% patients after LAAO with watchman 2.5 device with 99% being < 5mm leak
23. LAAO Registry: Peri device leak at 45 day follow up noted in 25% patients after LAAO with watchman 2.5 device with 99% being < 5mm leak
@ACCinTouch @ditchhaporia @avolgman @DrMarthaGulati @Drdevignair @DLBHATTMD @EdwardFryMD @KBerlacher @DrToniyaSingh @DrQuinnCapers4 @melsulistio @threadreaderapp unroll
• • •
Missing some Tweet in this thread? You can try to
force a refresh
